JP Morgan Chase
EVLO

JP Morgan Chase’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

JP Morgan Chase’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,162
Closed -$12.4K – 8100
2023
Q3 		$12.4K Buy
3,162
+2,962
+1,481% +$20.2K ﹤0.01% 6204
2023
Q2 		$650 Buy
200
+4
+2% +$12 ﹤0.01% 6512
2023
Q1 		$1K Buy
196
+19
+11% +$293 ﹤0.01% 6592
2022
Q4 		$6K Sell
177
-183
-51% -$7.24K ﹤0.01% 6143
2022
Q3 		$15K Buy
360
+107
+42% +$4.89K ﹤0.01% 5888
2022
Q2 		$11K Sell
253
-772
-75% -$35.8K ﹤0.01% 6021
2022
Q1 		$69K Buy
1,025
+209
+26% +$17.4K ﹤0.01% 5668
2021
Q4 		$99K Buy
816
+234
+40% +$39.5K ﹤0.01% 5690
2021
Q3 		$82K Sell
582
-1
-0.2% -$198 ﹤0.01% 5672
2021
Q2 		$160K Sell
583
-2,813
-83% -$710K ﹤0.01% 5344
2021
Q1 		$726K Buy
3,396
+777
+30% +$215K ﹤0.01% 4445
2020
Q4 		$633K Buy
2,619
+2,246
+602% +$278K ﹤0.01% 4239
2020
Q3 		$36K Buy
373
+137
+58% +$12.5K ﹤0.01% 5031
2020
Q2 		$23K Buy
236
+16
+7% +$1.4K ﹤0.01% 5011
2020
Q1 		$16K Sell
220
-6
-3% -$571 ﹤0.01% 4993
2019
Q4 		$18K Buy
226
+1
+0.4% +$112 ﹤0.01% 5334
2019
Q3 		$27K Buy
225
+36
+19% +$4.95K ﹤0.01% 5345
2019
Q2 		$34K Buy
189
+21
+13% +$3.4K ﹤0.01% 5317
2019
Q1 		$27K Sell
168
-8
-5% -$1.58K ﹤0.01% 5331
2018
Q4 		$46K Buy
176
+114
+184% +$22.9K ﹤0.01% 5112
2018
Q3 		$15K Buy
62
+8
+15% +$2.09K ﹤0.01% 5465
2018
Q2 		$13K Buy
+54
New +$15.7K ﹤0.01% 5352

Other funds holding EVLO

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

JP Morgan Chase's EVLO Position: Q4 2023 in Review

JP Morgan Chase sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2023, closing a stake of 3,162 shares — an estimated $12.4K sold.

JP Morgan Chase first reported a position in EVLO in Q2 2018 and held it in 22 quarters. The position peaked at $726K in Q1 2021. 2 funds tracked by Wall St. Rank hold EVLO as of Q4 2023.

  • JP Morgan Chase reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • JP Morgan Chase sold 3,162 Evelo Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $12.4K.
  • JP Morgan Chase first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 22 quarters.
  • JP Morgan Chase's Evelo Biosciences, Inc. Common Stock position peaked at $726K in Q1 2021.
  • 2 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2023.

Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.